Jump to content

Michael Abramoff

Add links
From Wikipedia, the free encyclopedia
Michael Abràmoff
Born (1963-03-07) March 7, 1963 (age 61)
Rotterdam, The Netherlands
Occupation(s)University of Iowa Professor of Ophthalmology and Visual Sciences, Professor of Electrical and Computer Engineering (ECE), Professor of Biomedical Engineering (BME)

Michael David Abràmoff (born 1963) is an American neuroscientist, ophthalmologist, vitreoretinal surgeon, computer engineer, and entrepreneur. He is the Watzke Professor of Ophthalmology and Visual Sciences at the Roy J. and Lucille A. Carver College of Medicine at the University of Iowa.[1]

Early life and education

[edit]

Abràmoff was born in Rotterdam, the Netherlands, and received his MD and MS (information theory) from the University of Amsterdam.[2] Abràmoff did his graduate research, leading to a Ph.D. in machine learning, at the University of Utrecht.[3]

Scientific and medical career

[edit]

He is inventor on over 60 US and international patents and patent applications primarily related to machine learning, artificial intelligence (AI) and imaging[4] Abràmoff was one of the early developers of ImageJ, a Java-based image processing program.[citation needed] He was the initiator behind the Iowa Reference Algorithms, a series of reference algorithms for OCT segmentation.[5]

Abràmoff has been a proponent of the theory that diabetes complications in the eye and brain are neural, not vascular, in origin,[6] based on his team's earlier finding that microvascular biomarkers of diabetic damage in the retina only occur after neurodegenerative changes.[7] Additionally, Abràmoff has been part of the Moonshot team (formally known as Restoring Vision: A JDRF Moonshot Initiative) from the outset.[8] Abràmoff started working on autonomous AI for diagnosis of retinal diseases during his residency in 1997, which led to the publishing of Low Level Screening of Exudates and Hemorrhages in Background Diabetic Retinopathy in 2000 and many other papers .[9] This research led to him receiving the nickname "The Retinator" in an Ophthalmology Times editorial in 2010,[10] referring to the work he had done to create the first autonomous AI diagnostic system. Roughly a decade later, the medical community's stance on healthcare AI had evolved, as evidenced by a 2019 American Medical Association (AMA) article on Abràmoff, titled This Ophthalmologist is Doing Health Care AI the Right Way.[11]

Abràmoff began working with regulators in 2010 to develop a process by which to introduce autonomous AI in healthcare.[citation needed] During that time, with his coworkers he developed "metrics for ethics" as a concept, as well as an ethical framework for healthcare AI, which led to an ongoing series of papers published through the Foundational Principles of Algorithmic Interpretation workgroup.[12][13]

After working with the FDA for over 8 years under this framework,[14] de novo clearance was granted to the autonomous AI product, IDx-DR (now LumineticsCore) on April 18, 2018, created by the company Abràmoff founded in 2010, Digital Diagnostics (formerly IDx) of Coralville Iowa.[15] That marked the first time that an autonomous diagnostic platform was cleared by the FDA in any field of medicine,[15] so that patients could legally be diagnosed by a computer rather than by a human.[citation needed] Abràmoff credits this achievement as well the subsequent national reimbursement, coding, and quality measurement, as well as widespread support by all healthcare stakeholders, on the ethical framework for AI in healthcare.[16] This work continues in collaboration with both FDA and other US and international regulatory authorities as well as CMS and other payor organizations including publication of an ethically founded AI reimbursement framework.[16]

Abràmoff is a founding member of FDA's Collaborative Community on Ophthalmic Imaging (CCOI), which was formed in 2019.[17] Abràmoff also chairs the Foundational Principles of Ophthalmic Imaging and Algorithmic Interpretation (FPOAI) Workgroup.[13] In 2019, Abràmoff founded the AI Healthcare Coalition[18] and serves as Executive Secretary, focusing on the policy implications of healthcare AI.

Business career

[edit]

Abràmoff founded three companies, EyeCheck, a teleretinal diabetic retinopathy screening company in Amsterdam, the Netherlands,[18] and i-Optics, an ophthalmic device company.[19]

In 2010, Abràmoff founded IDx Technologies, Inc., which has since rebranded as Digital Diagnostics[1] of which he is Executive Chairman.

In October 2017, in a Congressional Briefing sponsored by the Science Coalition, Abràmoff joined a panel of companies that spun out of U.S. research universities. The panelists highlighted to lawmakers the value of putting federal funds toward academic research.[20]

In January 2018, the results of a clinical trial for the first autonomous AI in primary care were submitted to FDA,[21] exceeding its pre-specified superiority endpoints for diagnostic accuracy. FDA assigned the LumineticsCore (then IDx-DR) system breakthrough device status for expedited review. In April 2018 FDA granted De Novo authorization to market this product in the US.[22]

Abràmoff has been called a "Renaissance Man" by Retina Physician [23] for creating a simple and more efficient process of autonomous AI for the retina that is in the best interest of the patient. [24]

In 2018, Abràmoff testified for the Federal Trade Commission on AI Predictive Analytics Through Real World Applications.[25]

Personal life

[edit]

Abràmoff served as an interviewer for Spielberg's Shoah Visual History Project.[26]

Awards and honours

[edit]
  • 2019 Fellow, Institute of Electrical and Electronics Engineers (IEEE)[27]

References

[edit]
  1. ^ a b "Michael D. Abramoff, MD, PhD | Department of Ophthalmology and Visual Sciences". Carver College of Medicine. Retrieved 2023-10-25.
  2. ^ "Michael Abramoff | Department of Ophthalmology and Visual Sciences". Carver College of Medicine. Retrieved 2023-10-25.
  3. ^ Abramoff, M. D. (2001-09-20). "Objective measurement of motion in the orbit". dspace.library.uu.nl. hdl:1874/395. Retrieved 2023-10-25.
  4. ^ "Patent Public Search Basic | USPTO. (n.d.). Ppubs.uspto.gov".
  5. ^ "Iowa Reference Algorithms: Human and Murine OCT Retinal Layer Analysis and Display | Iowa Institute for Biomedical Imaging - The University of Iowa". iibi.uiowa.edu. Retrieved 2023-10-25.
  6. ^ Lynch, Stephanie K.; Abràmoff, Michael D. (2017-10-01). "Diabetic retinopathy is a neurodegenerative disorder". Vision Research. Diabetic Retinopathy - an Overview. 139: 101–107. doi:10.1016/j.visres.2017.03.003. ISSN 0042-6989. PMC 5659971. PMID 28408138.
  7. ^ Sohn, Elliott H.; van Dijk, Hille W.; Jiao, Chunhua; Kok, Pauline H. B.; Jeong, Woojin; Demirkaya, Nazli; Garmager, Allison; Wit, Ferdinand; Kucukevcilioglu, Murat; van Velthoven, Mirjam E. J.; DeVries, J. Hans; Mullins, Robert F.; Kuehn, Markus H.; Schlingemann, Reinier Otto; Sonka, Milan (2016-05-10). "Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus". Proceedings of the National Academy of Sciences. 113 (19): E2655-64. Bibcode:2016PNAS..113E2655S. doi:10.1073/pnas.1522014113. ISSN 0027-8424. PMC 4868487. PMID 27114552.
  8. ^ "JDRF and The Mary Tyler Moore & S. Robert Levine, MD Charitable Foundation Launch Research Moonshot to Restore Vision in People with Diabetes-Related Eye Disease". StreetInsider.com. Retrieved 2023-10-25.
  9. ^ Abramoff MD, Staal J, Suttorp MSA, Polak BC, Viergever MA. Low level screening of exudates and hemorrhages in background diabetic retinopathy. Proceedings of the 1st International Workshop on Computer Assisted Fundus Image Analysis. Copenhagen, Denmark, May 29–30, 2000: 15.
  10. ^ "Revenge of the machines". Ophthalmology Times. 2010-07-01. Retrieved 2023-10-25.
  11. ^ "This ophthalmologist is doing health care AI the right way". American Medical Association. 2019-08-08. Retrieved 2023-10-25.
  12. ^ "Collaborative Community on Ophthalmic Imaging Foundation". cc-oi.org. Retrieved 2023-10-25.
  13. ^ a b Abràmoff, Michael D.; Cunningham, Brad; Patel, Bakul; Eydelman, Malvina B.; Leng, Theodore; Sakamoto, Taiji; Blodi, Barbara; Grenon, S. Marlene; Wolf, Risa M.; Manrai, Arjun K.; Ko, Justin M.; Chiang, Michael F.; Char, Danton; Abramoff, Michael; Blumenkranz, Mark (February 2022). "Foundational Considerations for Artificial Intelligence Using Ophthalmic Images". Ophthalmology. 129 (2): e14–e32. doi:10.1016/j.ophtha.2021.08.023. ISSN 0161-6420. PMC 9175066. PMID 34478784.
  14. ^ Abràmoff, Michael D.; Tobey, Danny; Char, Danton S. (March 12, 2020). "Lessons Learned About Autonomous AI: Finding a Safe, Efficacious, and Ethical Path Through the Development Process". American Journal of Ophthalmology. 214: 134–142. doi:10.1016/j.ajo.2020.02.022. ISSN 0002-9394. PMID 32171769. S2CID 212730809.
  15. ^ a b Commissioner, Office of the (2020-03-24). "FDA permits marketing of artificial intelligence-based device to detect certain diabetes-related eye problems". FDA. Retrieved 2023-10-25.
  16. ^ a b Abràmoff, Michael D.; Roehrenbeck, Cybil; Trujillo, Sylvia; Goldstein, Juli; Graves, Anitra S.; Repka, Michael X.; Silva III, Ezequiel "Zeke" (2022-06-09). "A reimbursement framework for artificial intelligence in healthcare". npj Digital Medicine. 5 (1): 72. doi:10.1038/s41746-022-00621-w. ISSN 2398-6352. PMC 9184542. PMID 35681002.
  17. ^ "Speakers & Panelists - Collaborative Community on Ophthalmic Imaging Foundation". cc-oi.org. Retrieved 2023-10-25.
  18. ^ a b "Members". AI Healthcare Coalition. Retrieved 2023-10-30.
  19. ^ Oprichting i-Optics Nederland B.V. Oprichting Besloten Vennootschap. [available from] Westvest Netwerk Notarissen, Delft (www.westvest-notarissen.nl) [Uitgegeven voor afschrift. Mr K.J. Van den Dool, Delft Notaris]
  20. ^ Ophthalmology, University of Iowa (2017-10-30), UI physician briefs Congress on how research spurs economy, retrieved 2023-10-25
  21. ^ "A Breakthrough in Diagnosing Diabetic Retinopathy". JDRF. 2018-02-05. Retrieved 2023-10-25.
  22. ^ "The Association for Research in Vision and Ophthalmology-". arvo.org. Retrieved 2023-10-25.
  23. ^ Helzner, Jerry (July 1, 2018). "Conversations in Retina: A Conversation With Michael Abramoff, MD, PhD – Automating the screening process for diabetic retinopathy". retinalphysician.com. Retrieved 2023-10-25.
  24. ^ "HIStalk Interviews Michael Abramoff, MD, PhD, President, IDx – HIStalk". histalk2.com. Retrieved 2023-10-25.
  25. ^ "FTC hearing: Not all AI is created equal, so safety and validation are critical". Healthcare IT News. 2018-11-14. Retrieved 2023-10-25.
  26. ^ Hoogendiuk, Oeke (May 24, 1996). "Zo groot, mooi en toegankelijk [So big, beautiful and accessible]". NIW: Nieuw Israelietisch Weekblad. 26(131): 26 (Steven Spielbergs Project pp 15-26).
  27. ^ "Three University of Iowa faculty members named IEEE Fellows | College of Engineering - The University of Iowa". engineering.uiowa.edu. Retrieved 2023-10-25.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Michael_Abramoff&oldid=1221778530"